Skip to main content
SpringerLink
Log in

Thrombocytopenia in Pregnancy: Fetal and Neonatal Alloimmune Thrombocytopenia

  • Chapter
Disorders of Thrombosis and Hemostasis in Pregnancy

  • 1264 Accesses

Abstract

Fetal/neonatal alloimmune thrombocytopenia (FNAIT) results from the formation by the mother of antibodies that are directed against a fetal platelet alloantigen inherited from its father. The maternal alloantibodies cross the placenta and destroy the baby’s platelets, and the resulting fetal thrombocytopenia may cause bleeding, particularly into the brain, before or shortly after birth. Approximately 10–20 % of affected fetuses have intracranial hemorrhages, one quarter to one half of which occur in utero. There are considerable controversies regarding the optimal management of FNAIT-affected pregnancies. There is no clear approach to the antenatal management of first affected pregnancies, and several questions remain around the approaches to the management of second and subsequent affected pregnancies. Currently, antenatal management of FNAIT consists of weekly maternal intravenous immunoglobulin (IVIg) infusions, with or without oral steroid therapy – the optimal steroid dosages and protocols remain to be defined. Some centers continue to offer serial intrauterine platelet transfusions as first-line therapy, but the multiple cordocenteses required to administer the platelets carry substantial risk of fetal demise. Potential techniques for antenatal screening of first pregnancies are being developed. Postnatal screening does not prevent neonatal morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moulinier J. Alloimmunisation maternelle antipla-quettaire duzo. In: Proceedings of the 6th congress of the European society of haematology. Paris: European Society of Hematology; 1953. p. 817–20.

    Google Scholar 

  2. Shulman NR, Marder VJ, et al. Platelet and leukocyte isoantigens and their antibodies: serologic physiologic and clinical studies. Prog Hematol. 1964;4:222–304.

    CAS  PubMed  Google Scholar 

  3. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993;329:1463–6.

    CAS  PubMed  Google Scholar 

  4. Blanchette VS, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol. 2000;13:365–90.

    CAS  PubMed  Google Scholar 

  5. Kaplan C, Murphy MF. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids – more questions than answers. European Working Group on FMAIT. Br J Haematol. 1998;100(1):62–5.

    CAS  PubMed  Google Scholar 

  6. Kaplan C, Forestier F, Daffos F. Management of fetal and neonatal alloimmune thrombocytopenia. Transfus Med Rev. 1996;10:233–40.

    CAS  PubMed  Google Scholar 

  7. Murphy MF, Williamson LM. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK National Screening Committee. Br J Haematol. 2000;111:726–32.

    CAS  PubMed  Google Scholar 

  8. Proulx C, Filion M, Goldman M. Analysis of immunoglobulin class, IgG subclass and titre of HPA-1a antibodies in alloimmunized mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol. 1994;87:813–7.

    CAS  PubMed  Google Scholar 

  9. Rothenberger S. Neonatal alloimmune thrombocytopenia. Ther Apher. 2002;6:32–5.

    PubMed  Google Scholar 

  10. Kaplan C. Platelet alloimmunity: the fetal/neonatal alloimmune thrombocytopenia. Vox Sang. 2002;83 Suppl 1:289–91.

    CAS  PubMed  Google Scholar 

  11. Murphy MF, Manley R, Roberts D. Neonatal alloimmune thrombocytopenia. Haematologica. 1999;84:110–4.

    PubMed  Google Scholar 

  12. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol. 2001;41:45–55.

    CAS  PubMed  Google Scholar 

  13. Blanchette VS, Chen L, de Friedberg ZS. Alloimmunisation to the PlA1 platelet antigen: results of a prospective study. Br J Haematol. 1990;74:209–15.

    CAS  PubMed  Google Scholar 

  14. Kamphuis MM, Paridaans N, Porcelijn L, De Haas M, van der Schoot CE, Brand A, Bonsel GJ, Oepkes D. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG. 2010;117(11):1335–43.

    CAS  PubMed  Google Scholar 

  15. Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Hauge R. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neo-natal alloimmune thrombocytopenia. Blood. 2007;110:833.

    CAS  PubMed  Google Scholar 

  16. Mueller-Eckhardt C, Mueller-Eckhardt G, Willen-Ohff H, Horz A, Kuenzlen E, O’Neill GJ. Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLAB8 and DR3. Tissue Antigens. 1985;26:71–6.

    CAS  PubMed  Google Scholar 

  17. Turner ML, Bessos H, Fagge T. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion. 2005;45:1945–56.

    CAS  PubMed  Google Scholar 

  18. Decary F, L’Abbe D, Tremblay L. The immune response to the HPA-1a antigen: association with HLA-DRw52a. Transfus Med. 1991;1:55–62.

    CAS  PubMed  Google Scholar 

  19. Mueller-Eckhardt C, Santoso S, Kiefel V. Platelet alloantigens molecular, genetic, and clinical aspects. Vox Sang. 1994;67S3:89–93.

    Google Scholar 

  20. Doughty HA, Murphy MF, Metcalfe P. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study. Br J Haematol. 1995;90:321–5.

    CAS  PubMed  Google Scholar 

  21. Jaegtvik S, Husebekk A, Aune B. Neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. Br J Obstet Gynaecol. 2000;107:691–4.

    CAS  Google Scholar 

  22. Valentin N, Vergracht A, Bignon JD. HLA-DRw52a is involved in alloimmunization against PL-A1 anti-gen. Hum Immunol. 1990;27:73–9.

    CAS  PubMed  Google Scholar 

  23. Reznikoff-Etievant MF. Management of alloimmune neonatal and antenatal thrombocytopenia. Vox Sang. 1988;55:193–201.

    CAS  PubMed  Google Scholar 

  24. Mueller-Eckhardt C, Grubert A, Weisheit M. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363–6.

    CAS  PubMed  Google Scholar 

  25. Kornfeld I, Wilson RD, Ballem P. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia. Fetal Diagn Ther. 1996;11:210–7.

    CAS  PubMed  Google Scholar 

  26. Letsky EA, Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Br J Haematol. 1996;95:21–6.

    CAS  PubMed  Google Scholar 

  27. Khouzami AN, Kickler TS, Callan NA. Devastating sequelae of alloimmune thrombocytopenia: an entity that deserves more attention. J Matern Fetal Med. 1996;5:137–41.

    CAS  PubMed  Google Scholar 

  28. Kanhai HHH, Porcelijn L, van Zoeren D. Antenatal care in pregnancies at risk of alloimmune thrombocytopenia: report of 19 cases in 16 families. Eur J Obstet Gynecol Reprod Biol. 1996;68:67–73.

    CAS  PubMed  Google Scholar 

  29. Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol. 1997;14:415–8.

    CAS  PubMed  Google Scholar 

  30. Davoren A, McParland P, Barnes CA. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol. 2002;55:289–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Davoren A, Curtis BR, Aster RH. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Immunohematology. 2004;44:1220–5.

    CAS  Google Scholar 

  32. Rayment R, Birchall J, Yarranton H, Hewertson J, Allen D, Murphy MF. Neonatal alloimmune thrombocytopenia. BMJ. 2003;327:331–2.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Mandelbaum M, Koren D, Eichelberger B. Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia, with emphasis on human platelet antigen-15 alloimmunization. Vox Sang. 2005;89:39–43.

    CAS  PubMed  Google Scholar 

  34. Ertel K, Al-Tawil M, Santoso S. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion. 2005;45:366–73.

    CAS  PubMed  Google Scholar 

  35. Kroll H, Yates J, Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion. 2005;45:353–8.

    CAS  PubMed  Google Scholar 

  36. Porcelijn L, Huiskes E, Overbeeke M. Rare anti HPA-5a NAIT cases. Vox Sang. 2006;91S2:Abstract 55.

    Google Scholar 

  37. Ahya R, Turner ML, Urbaniak SJ. Fetomaternal alloimmune thrombocytopenia. Transfus Apher Sci. 2001;25:139–45.

    CAS  PubMed  Google Scholar 

  38. Birchall J, Murphy MF, Kaplan C. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol. 2003;122:275–88.

    PubMed  Google Scholar 

  39. Kaplan C, Morel-Kopp MC, Clemenceau S. Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy. Transfus Med. 1992;2:265–71.

    CAS  PubMed  Google Scholar 

  40. Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: myth or meaningful? Transfus Med Rev. 2000;14:275–80.

    CAS  Google Scholar 

  41. Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med. 1992;2:181–8.

    CAS  PubMed  Google Scholar 

  42. Bertrand G, Jallu V, Gouet M. Quantification of human platelet antigen-1a antibodies with monoclonal antibody immobilization of platelet antigens procedure. Transfusion. 2005;45:1319–23.

    CAS  PubMed  Google Scholar 

  43. Goldman M, Trudel E, Richard L. Report on the eleventh international society of blood transfusion platelet genotyping and serology workshop. Vox Sang. 2003;85:149–55.

    CAS  PubMed  Google Scholar 

  44. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev. 2002;16:69–72.

    CAS  PubMed  Google Scholar 

  45. Killie MK, Kjeldsen-Kragh J, Skogen B. Maternal anti-HPA1a antibody level as predictive value in neo-natal alloimmune thrombocytopenic purpura (NAITP). Blood. 2004;104:Abstract 2072.

    Google Scholar 

  46. Meyer O, Agaylan A, Borchert H. A simple and practical assay for the antigen-specific detection of platelet antibodies. Transfusion. 2006;46:1226–31.

    PubMed  Google Scholar 

  47. Bussel JB, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillieres Clin Haematol. 2007;11:391–408.

    Google Scholar 

  48. Sainio S, Teramo K, Kekomaki R. Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med. 1999;9:321–30.

    CAS  PubMed  Google Scholar 

  49. Berkowitz RL, Kolb A, Mcfarland JG. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107:91–6.

    PubMed  Google Scholar 

  50. Bussel JB, Skupski DW, Mcfarland JG. Fetal alloimmune thrombocytopenia: consensus and controversy. J Matern Fetal Med. 1996;5:281–92.

    CAS  PubMed  Google Scholar 

  51. Kuhn MJ, Couch SM, Binstadt DH. Prenatal recognition of central nervous system complications of alloimmune thrombocytopenia. Comput Med Imaging Graph. 1992;16:137–42.

    CAS  PubMed  Google Scholar 

  52. Stanworth SJ, Hackett G, Williamson LM. Feto-maternal alloimmune thrombocytopenia presenting antenatally as hydrops fetalis. Prenat Diagn. 2001;21:418–24.

    Google Scholar 

  53. Bussel JB. Immune thrombocytopenia in pregnancy: autoimmune and allo-immune. J Reprod Immunol. 1997;37:35–61.

    CAS  PubMed  Google Scholar 

  54. Kaplan C, Daffos F, Forestier F. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood. 1988;72:340–3.

    CAS  PubMed  Google Scholar 

  55. Murphy MF, Williamson LM, Urbaniak SJ. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it? Vox Sang. 2002;83 Suppl 1:409–16.

    PubMed  Google Scholar 

  56. Van den Akker ES, Oepkes D, Lopriore E, Brand A, Kanhai HH. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG. 2007;114(4):469–73.

    PubMed  Google Scholar 

  57. Bussel JB, Berkowitz RL, McFarland JG. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med. 1988;319:1374–8.

    CAS  PubMed  Google Scholar 

  58. Ohto H, Yamaguchi T, Takeuchi C. Anti-HPA-5b-induced neonatal alloimmune thrombocytopenia: antibody titre as predictor. Br J Haematol. 2000;110:223–7.

    CAS  PubMed  Google Scholar 

  59. Killie MK, Husebekk A, Kjeldsen-Kragh J. Significance of antibody quantification. Vox Sang. 2006;91:15. Abstract 51.

    Google Scholar 

  60. BCSH guidelines, Gibson BES, Bolton-Maggs PHB, Pamphilon D, et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004;124:433–53;2005 amendment to these guidelines: www.bcshguidelines.com.

  61. Bessos H, Turner M, Urbaniak SJ. Is there a relation-ship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia? Immunohematology. 2005;21:102–8.

    CAS  PubMed  Google Scholar 

  62. Lyou JY, Chen YJ, Hu HY. PCR with sequence-specific primer-based simultaneous genotyping of human platelet antigen-1 to -13w. Transfusion. 2002;42:1089–95.

    CAS  PubMed  Google Scholar 

  63. Peterson JA, Balthazor SM, Curtis BR. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max-a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion. 2005;45:1487–95.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Chaoying M, Junwu G, Chituwo BM. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J Trop Pediatr. 1999;45:237–9.

    Google Scholar 

  65. Tiller H, Kamphuis MM, Flodmark O, Papadogiannakis N, David AL, Sainio S, Koskinen S, Javela K, Wikman AT, Kekomaki R, Kanhai HH, Oepkes D, Husebekk A, Westgren M. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open. 2013;3(3). pii:e002490. doi:10.1136/bmjopen-2012-002490.

  66. Radder CM, Kanhai HH, Brand A. On the mechanism of high dose maternal intravenous immunoglobulin (IVIG) in alloimmune thrombocytopenia. In: Management of fetal alloimmune thrombocytopenia. Amsterdam: Print Partners Ipskamp; 2004. p. 69–81.

    Google Scholar 

  67. Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Cur- rent trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Kaplan-Gouet C, Schlegel N, Salmon C, McGregor J, editors. Platelet immunology: fundamental and clinical aspects. Paris: Colloque INSERM/John Libbey Eurotext; 1991. p. 267–78.

    Google Scholar 

  68. Prouix C, Filion M, Goldman M, Bradley A, Devine D, Decary F, Chartrand P. Analysis of immunoglobulin class, IgG subclass and titre of HPA-1a antibodies in alloimmunised mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol. 1994;87:813–7.

    Google Scholar 

  69. Marzusch K, Fischer Dietl J, Wiest E, Volklein K, Schnaid M. Difficulties in the antenatal assessment of neonatal alloimmune thrombocytopenia. Acta Obstet Gynecol Scand. 1993;72:583–5.

    CAS  PubMed  Google Scholar 

  70. Bertrand G, Martageix C, Jallu V. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost. 2006;4:628–37.

    CAS  PubMed  Google Scholar 

  71. Ghevaert C, Campbell K, Stafford P, Metcalfe P, Casbard A, Smith GA, Allen D, Ranasinghe E, Williamson LM, Ouwehand WH. HPA-1a antibody potency and bioactivity do not predict severity of feto-maternal alloimmune thrombocytopenia. Transfusion. 2007;7:1296–305.

    Google Scholar 

  72. Ino H, Torigoe K, Numata O. A case of neonatal alloimmune thrombocytopenic purpura by anti-HPA-4b with intracranial hemorrhage. J Jpn Pediatr Soc. 2000;104:682–5.

    Google Scholar 

  73. Radder CM, Kanhai HH, de Beaufort AJ. Evaluation of gradual conversion to a less invasive therapeutic strategy for pregnant women with alloimmune thrombocytopenia in the fetus for prevention of intracranial hemorrhage. Ned Tijdschr Geneeskd. 2000;144:2015–8.

    CAS  PubMed  Google Scholar 

  74. Murphy MF, Pullon HWH, Metcalfe P, Chapman JF, Jenkins E, Waters AH. Management of fetal alloimmune thrombocytopenia by weekly in utero platelet transfusions. Vox Sang. 1990;58:45–9.

    CAS  PubMed  Google Scholar 

  75. Murphy MF, Waters AH, Doughty HA, Hambley H, Mibashan RS, Nicolaides K. Antenatal management of fetal alloimmune thrombocytopenia. Transfus Med. 1994;4:281–92.

    CAS  PubMed  Google Scholar 

  76. Paidas MJ, Berkowitz RL, Lynch L, Lockwood CJ, Lapinski R, McFarland JG. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol. 1995;172:475–9.

    CAS  PubMed  Google Scholar 

  77. Simsek S, Christiaens GCLM, Kanhai HHH. Human platelet antigen-1 (Zw) typing of fetuses by analysis of polymerase chain reaction-amplified genomic DNA from amniocytes. Transfus Med. 1994;4:15–9.

    CAS  PubMed  Google Scholar 

  78. Overton TG, Duncan KR, Jolly M, Letsky E, Fisk NM. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and peri-natal outcome. Am J Obstet Gynecol. 2002;186(4):826–31.

    PubMed  Google Scholar 

  79. Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomised controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):249–55.

    CAS  PubMed  Google Scholar 

  80. Nicolini U, Kochenour NK, Greco P, Letsky EA, Johnson RD, Contreras M. Consequences of fetomaternal haemorrhage after intrauterine transfusion. BMJ. 1988;297:1379–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Radder CM, Roelen DL, Van de Meer-Prins EM, Claas FHJ, Kanhai HHH, Brand A. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2004;191:815–20.

    CAS  PubMed  Google Scholar 

  82. Radder CM, de Haan MJJ, Brand A, Stoelhorst GMSJ, Veen S, Kanhai HHH. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev. 2004;80:65–76.

    PubMed  Google Scholar 

  83. Zimmermann R, Huch A. In utero therapy with immunoglobulin for alloimmune thrombocytopenia. Lancet. 1992;340:1034–5.

    Google Scholar 

  84. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484–6.

    CAS  PubMed  Google Scholar 

  85. Clark AL, Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol. 1998;176:241–53.

    Google Scholar 

  86. Bussel JB, Berkowitz RL, Lynch L, Lesser ML, Paidas MJ, Huang CL. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996;174(5):1414–23.

    CAS  PubMed  Google Scholar 

  87. Gaddipati S, Berkowitz RL, Lembet AA. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol. 2001;185:976–80.

    CAS  PubMed  Google Scholar 

  88. Lynch L, Bussel JB, McFarland JG, Chitkara U, Berkowitz RL. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol. 1992;80:67–71.

    CAS  PubMed  Google Scholar 

  89. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2001;185:683–8.

    CAS  PubMed  Google Scholar 

  90. Kroll H, Kiefel V, Giers G, Bald R, Hoch J, Hanfland P. Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfus Med. 1994;4(4):293–6.

    CAS  PubMed  Google Scholar 

  91. Van den Akker ESA, Westgren M, Husbekk A, Kanhai HHH, Oepkes D. Fetal or neonatal alloimmune thrombocytopenia: a new randomized con-trolled trial and international multicenter data collection [abstract]. J Obstet Gynaecol. 2006;26 Suppl 1:S63.

    Google Scholar 

  92. Ward MJ, Pauliny J, Lipper EG, Bussel JB. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. Am J Perinatol. 2006;23(8):487–92.

    PubMed  Google Scholar 

  93. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, Tsaur FW, Macfarland JG. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010;203(2):135.e1–14.

    Google Scholar 

  94. Paternoster DM, Cester M, Memmo A. The management of feto-maternal alloimmune thrombocytopenia: report of three cases. J Matern Fetal Neonatal Med. 2006;19:517–20.

    CAS  PubMed  Google Scholar 

  95. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev. 2011;(5):CD004226. doi:10.1002/14651858.CD004226.pub3.

  96. Bennett PR, Warwick R, Vaughan J. Prenatal determination of human platelet antigen type using DNA amplification following amniocentesis. Br J Obstet Gynaecol. 1994;101:246–9.

    CAS  PubMed  Google Scholar 

  97. Sainio S, Jarvenpaa AL, Renlund M. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol. 2000;95:441–6.

    CAS  PubMed  Google Scholar 

  98. Bennett PR, Vaughan J, Handyside A. Potential for pre-implantation determination of human platelet antigen type using DNA amplification: a strategy for prevention of allo-immune thrombocytopenia. Fetal Diagn Ther. 1994;9:229–32.

    CAS  PubMed  Google Scholar 

  99. Radder CM, Brand A, Kanhai HHH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang. 2003;84:318–25.

    CAS  PubMed  Google Scholar 

  100. Deruelle P, Wibaut B, Manessier L, Subtil D, Vaast P, Puech F, Valat AS. Is a non-invasive management allowed for maternofetal alloimmune thrombocytopenia? Experience over a 10-year period. Gynecol Obstet Fertil. 2007;35(3):199–204.

    CAS  PubMed  Google Scholar 

  101. Kanhai HH, van den Akker ES, Walther FJ, Brand A. Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage. Fetal Diagn Ther. 2006;21(1):55–60.

    PubMed  Google Scholar 

  102. Glade-Bender J, McFarland JG, Kaplan C, Porcelijn L, Bussel JB. Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr. 2001;138:862–7.

    CAS  PubMed  Google Scholar 

  103. Kaplan C, Morel-Kopp MC, Kroll H, Kiefel V, Sohlege N, Chesnel N, Mueller-Eckhardt C. HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol. 1991;78:425–9.

    CAS  PubMed  Google Scholar 

  104. Friedman JM, Aster RH. Neonatal alloimmune thrombocytopenic purpura and congenital porencephaly in two siblings associated with a “new” maternal antiplatelet antibody. Blood. 1985;65:1412–5.

    CAS  PubMed  Google Scholar 

  105. Gyamfi C, Eddleman KA. Alloimmune thrombocytopenia. Clin Obstet Gynecol. 2005;48:897–909.

    PubMed  Google Scholar 

  106. Van den Akker E, Oepkes D, Brand A, Kanhai HH. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia? BJOG. 2006;113(7):781–3.

    PubMed  Google Scholar 

  107. Sia CG, Amigo NC, Harper RG. Failure of cesarean section to prevent intracranial hemorrhage in siblings with isoimmune neonatal thrombocytopenia. Am J Obstet Gynecol. 1985;153:79–81.

    CAS  PubMed  Google Scholar 

  108. te Pas AB, Lopriore E, van den Akker ES, Oepkes D, Kanhai HH, Brand A, Walther FJ. Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG. Eur J Pediatr. 2007;166(10):1057–63.

    Google Scholar 

  109. Berkowitz R, Bussel JB, Hung C, Wissert M. A randomised prospective treatment trial for patients with “standard risk” alloimmune thrombocytopenia (AIT). Am J Obstet Gynecol. 2006;195 Suppl 1:S23.

    Google Scholar 

  110. Gafni A, Blanchette VS. Screening for alloimmune thrombocytopenia: an economic perspective. Curr Stud Hematol Blood Transfus. 1988;54:140–7.

    PubMed  Google Scholar 

  111. Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-effectiveness of ante-natal screening for neonatal alloimmune thrombocytopenia. BJOG. 2007;114:588–95.

    CAS  PubMed  Google Scholar 

  112. Kjedsen-Kragh J, Husebekk A, Kjaer Killie M, Skogen B. Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health program? Transfus Apher Sci. 2008;38:183–8.

    Google Scholar 

  113. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, Uzan S, Dreyfus M, Kaplan C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol. 1996;13:423–31.

    CAS  PubMed  Google Scholar 

  114. Williamson LM, Hackett G, Rennie J. The natural history of fetomaternal alloimmunization to the platelet-specific antigen hpa-1a (pi-a1, zw-a) as determined by antenatal screening. Blood. 1998;92:2280–7.

    CAS  PubMed  Google Scholar 

  115. Tiller H, Killie MK, Skogen B, Øian P, Husebekk A. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG. 2009;116(4):594–8.

    CAS  PubMed  Google Scholar 

  116. Kaplan C. Alloimmune thrombocytopenia of the fetus and neonate: prospective antenatal screening. Third European symposium on platelet and granulocyte immunobiology, Cambridge; 26–29 June 1994.

    Google Scholar 

  117. Husebekk A, Killie MK, Kjeldsen-Kragh J. General overview over screening programs. Vox Sang. 2006;91:15. Abstract 49.

    Google Scholar 

  118. Husebekk A, Killie MK, Kjeldsen-Kragh J, Skogen B. Is it time to implement HPA-1 screening in pregnancy? Curr Opin Hematol. 2009;16(6):497–502.

    PubMed  Google Scholar 

  119. Berkowitz RL, Bussel JB, Mc Farland JG. Alloimmune thrombocytopenia: state of the art. Am J Obstet Gynecol. 2006;195:907–13.

    PubMed  Google Scholar 

  120. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol. 2007;136:366–78.

    PubMed  Google Scholar 

  121. Beachy J. Neonatal alloimmune thrombocytopenia: a case study (Lab Values). Neonatal Netw J Neonatal Nurs. 2011;30(6):407.

    Google Scholar 

  122. Peterson JA, Pechauer SM, Gitter ML, Kanack A, Curtis BR, Reese J, et al. New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopenia. Transfusion. 2012;52(5):1117–24.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Women’s Health Services, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, Stadium Road, London, SE18 4QH, UK

    Sukrutha Veerareddy BSc, MBBS, MRCOG, PhD

  2. Fetal Medicine Unit, University College London Hospitals NHS Foundation Trust, 1 Elizabeth Garrett Anderson Wing, 25 Grafton Way, London, WC1E 6DB, UK

    Pranav P. Pandya BSc, MBBS, MD, FRCOG

Authors
  1. Sukrutha Veerareddy BSc, MBBS, MRCOG, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pranav P. Pandya BSc, MBBS, MD, FRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pranav P. Pandya BSc, MBBS, MD, FRCOG .

Editor information

Editors and Affiliations

  1. Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Hannah Cohen

  2. Institute for Women's Health, University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Patrick O'Brien

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Veerareddy, S., Pandya, P.P. (2015). Thrombocytopenia in Pregnancy: Fetal and Neonatal Alloimmune Thrombocytopenia. In: Cohen, H., O'Brien, P. (eds) Disorders of Thrombosis and Hemostasis in Pregnancy. Springer, Cham. https://doi.org/10.1007/978-3-319-15120-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-15120-5_16

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-15119-9

  • Online ISBN: 978-3-319-15120-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation